Bio Protocol, a project combining artificial intelligence and blockchain for the decentralized science (DeSci) sector, has successfully closed a $6.9 million funding round.
The round was led by Maelstrom Fund, founded by BitMEX co-founder Arthur Hayes, with participation from Mechanism Capital, Animoca Brands, Presto Labs, and several other investors.
Expanding AI and DeSci Capabilities
According to the team, the new capital will support the development of the platform’s AI-powered scientific software, as well as the integration of new on-chain features. These include prediction markets, credit systems, and AI-agent communication tools.
Bio Protocol aims to enable researchers, patients, and the crypto community to collaborate within AI-driven networks that can automate scientific processes, generate hypotheses, and monetize discoveries.
Bio V2 Launch
The fundraising coincides with the release of Bio V2, an upgrade introducing:
- Ignition Sales – an on-chain funding mechanism for AI agents and tokenized intellectual property,
- BioXP – a rewards program for community engagement and participation in research,
- BIO token staking.
In addition, the company highlighted the launch of its first BioAgent, Aubrai, in August 2025 in collaboration with VitaDA. Since its debut, Aubrai has attracted over $900,000, generated nearly 1,000 blockchain-verified hypotheses, and contributed to the growth of the AUBRAI token.
Vision for the Future
Paul Kohlhaas, CEO of Bio Protocol, emphasized that the startup’s mission is to merge AI, biotechnology, and crypto to accelerate the journey from concept to treatment—from decades down to just a few months.
